Chikungunya virus and prospects for a vaccine
Autor(es): Weaver Scott C, Osorio Jorge E, Livengood Jill A, Chen Rubing, Stinchcomb Dan T
Resumo: In 2004, chikungunya virus (CHIKV) re-emerged from East Africa to cause devastating epidemics of debilitating - often chronic arthralgia that have affected millions of people in the Indian Ocean Basin - Asia. More limited epidemics initiated by travelers subsequently occurred in Italy - France, as well as human cases exported to most regions of the world, including the Americas where CHIKV could become endemic. Because CHIKV circulates during epidemics in an urban mosquito-human cycle, control of transmission relies on mosquito abatement, which is rarely effective. Furthermore, there is no antiviral treatment for CHIKV infection - no licensed vaccine to prevent disease. Here, we discuss the challenges to the development of a safe, effective - affordable chikungunya vaccine - recent progress toward this goal.
Palavras-Chave: Alphavirus; Antibody; Chikungunya; Emergence; Evolution; Mosquito; Vaccine
Imprenta: Expert Review of Vaccines, v. 11, n. 9, p. 1087-1101, 2012
Identificador do objeto digital: 10.1586/erv.12.84
Descritores: Chikungunya virus - Cytopathology ; Chikungunya virus - Pathogenesis ; Chikungunya virus - Viral infections ; Chikungunya Virus - Virus ; Chikungunya virus - Transmission ; Chikungunya virus - Vaccine ; Chikungunya virus - Chikungunya fever ; Chikungunya virus - Epidemic ; Chikungunya virus - Epidemiology ; Chikungunya virus - Immunology
Data de publicação: 2012
